TFF Pharmaceuticals (TFFP)
(Delayed Data from NSDQ)
$2.21 USD
+0.17 (8.33%)
Updated May 24, 2024 03:59 PM ET
After-Market: $2.21 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth C Momentum D VGM
Brokerage Reports
0 items in cart
TFF Pharmaceuticals, Inc. [TFFP]
Reports for Purchase
Showing records 21 - 40 ( 149 total )
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
More Funding Received from Leidos Related to DARPA PPB Military Program
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q22: Focused On Internal Programs, 10-K Filing Allows For Model Update
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
TFF VORI and TFF TAC Phase 2 Proof-of-Concept Data on Track for Late 2023; Reiterate Buy and $22 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Call Highlights Internal Program Focus, Rational Timeline Communication
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Replaces CEO with Harlan Weisman, an Accomplished Healthcare Executive
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Encouraging POC Results With TFF VORI Compassionate Use Bode Well for a Positive Phase 2; Reit. Buy and $22 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q22: Phase 2 Data Coming Over 1H23, Still Awaiting a Revenue Bearing Deal
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Collaborates With Aptar Pharma On Intranasal Dry Powder Vaccines & Drugs
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
TFF VORI & TFF TAC Data Now In 1H23, Second TFF VORI Patient Benefiting
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Several Posters At AAPS Meeting Underscore Benefits of Thin Film Freezing
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Presents Positive Anecdotal Data from Transplant Patient Taking TFF VORI
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J